Streamlining Detection of Fusion Genes in Colorectal Cancer: Having "Faith" in Precision Oncology in the (Tissue) "Agnostic" Era.
MetadataShow full item record
The FDA recently granted tissue-agnostic approval for the first-in-class TRK inhibitor larotrectinib for patients whose tumors harbor fusions in neurotrophic receptor tyrosine kinases. These fusion genes have a frequency of less than 1% in unselected patients with colorectal cancer. Using a multiomics approach and a clinically annotated cohort of patients with colorectal cancer, Cocco and colleagues showed that patients with sporadic, RAS/BRAF wild-type, mismatch repair-deficient colorectal cancer tumors with MLH1 promoter methylation present fusions in kinase genes in 42% of cases and suggested a diagnostic framework to improve the selection of patients eligible for gene fusion testing.See related article by Cocco et al., p. 1047.
Gastrointestinal Cancer Biology and Genomics
License start date
Cancer research, 2019, 79 (6), pp. 1041 - 1043